Beam Therapeutics (Nasdaq: BEAM) reported a net loss of $122.7 million, or $1.18 per share, for the second quarter of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE